IRONWOOD PHARMA INC CLASS A (IRWD)
Health Care · Specialty pharmaceuticals - gastrointestinal and rare diseases · NASDAQ
A profitable biotech specializing in GI therapies anchored by LINZESS, with a pipeline led by apraglutide for rare short bowel syndrome.
What IRONWOOD PHARMA INC CLASS A does
Ironwood Pharmaceuticals is a biotechnology company developing and commercializing therapies for gastrointestinal and rare diseases. Its commercial product LINZESS (linaclotide) is a GC-C agonist approved for IBS-C, chronic idiopathic constipation, and functional constipation in adults and pediatric patients. The company is also advancing apraglutide, a GLP-2 analog, for short bowel syndrome patients dependent on parenteral support.
Themes: ["Gastrointestinal disorders / IBS-C and chronic constipation","Rare diseases / short bowel syndrome","GLP-2 agonists"]
Fundamentals
- Price$4.67 as of 2026-07-09 close
- Market cap$777M as of 2026-07-10
- 1-year return+483.8% as of 2026-07-09 close
- P/E7.60 as of 2026-07-10
- Net margin+28.3% as of 2026-07-10
- Gross margin+100.0% as of 2026-07-10
- ROE+29.3% as of 2026-07-10
- Debt / equity0.56 as of 2026-07-10
- Revenue growth (YoY)+13.8% as of 2026-07-10
- Revenue CAGR (3y)-10.3% SEC XBRL
- Beta0.21 as of 2026-07-10
Key risks (from latest filing)
["Apraglutide requires a confirmatory Phase III clinical trial (STARS-2) for NDA approval following pharmacokinetic analysis showing lower-than-planned exposure in the initial STARS trial; trial initiation expected Q2 2026 with uncertain timeline and regulatory outcome.","LINZESS revenue declined $51.1 million in 2025 compared to 2024 due to net price pressure and inventory channel fluctuations, with reliance on strategic partnerships (AbbVie, AstraZeneca, Astellas) for commercialization outside the U.S.","The company carries significant debt ($199.9 million current convertible notes and $385 million revolving credit facility) with a stockholders' deficit of $217.1 million as of March 31, 2026, limiting financial flexibility."]
Competitors & peers
- AbbVie (ABBV)
- AstraZeneca (AZN)
- Astellas Pharma (ASTP)
Fundamentals: Finnhub, as of 2026-07-10. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-07-09.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & Finnhub, shown with their as-of date.